Examining physician payments tied to GLP-1 drugs

A Washington Post investigation found that Eli Lilly and Novo Nordisk paid more than $270 million to physicians and other prescribers between 2018 and 2025. Partnerships between drugmakers an clinicians have been around for years, and they are legal. On The Gist Healthcare Podcast, Washington Post data reporter Lydia Sidhom discusses how the companies’ outreach has expanded across the medical community and what the federal data can and cannot tell us about those payments.

Further reading: The largely hidden force helping drive America’s craze for weight-loss drugs (Washington Post)